AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly ...

AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

“We sit in the low 60s in terms of Botox share, and that's a clear leadership position by a large margin in the U.S.,” AbbVie ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

Scotiabank analyst Louise Chen maintained a Buy rating on AbbVie today and set a price target of $280.00. Chen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Vertex ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its ...

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...

AbbVie is seeking European approval of expanded use of its migraine drug atogepant in adults following strong results from a ...